IFN-γ production in NY-ESO-1+-sorted T-cells showed that NY-ESO-1-peptide-expanded T-cells were able to react against naturally processed and presented peptides on HLA-A2+ tumor cell lines. This evidence concerns the gene IFNG and neoplasm.